Furthermore, analyses of surgical specimens from HER2-positive breast cancers have previously revealed an increase in NK cells in tumor tissue after trastuzumab treatment, relative to specimens collected either before treatment (1) or from case-matched controls who did not receive trastuzumab treatment (2). This evidence concerns the gene ERBB2 and neoplasm.